NBIX · Categories · Upgrades
NBIX - Analyst upgrades
Neurocrine Biosciences Inc. (NBIX) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for NBIX
- Neurocrine Biosciences upgraded by Needham with a new price targetNeedham upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $138.00
- Neurocrine Biosciences upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Neurocrine Biosciences from Sector Perform to Outperform and set a new price target of $137.00
- Neurocrine Biosciences upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $159.00 from $131.00 previously
- Neurocrine Biosciences upgraded by Wells Fargo with a new price targetWells Fargo upgraded Neurocrine Biosciences from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously
- Neurocrine Biosciences upgraded by SVB Securities with a new price targetSVB Securities upgraded Neurocrine Biosciences from Market Perform to Outperform and set a new price target of $125.00 from $115.00 previously
- Neurocrine Biosciences upgraded by BMO Capital Markets with a new price targetBMO Capital Markets upgraded Neurocrine Biosciences from Underperform to Market Perform and set a new price target of $96.00 from $91.00 previously
- Neurocrine Biosciences upgraded by Guggenheim with a new price targetGuggenheim upgraded Neurocrine Biosciences from Neutral to Buy and set a new price target of $145.00
- Neurocrine Biosciences upgraded by Canaccord Genuity with a new price targetCanaccord Genuity upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $132.00 from $124.00 previously
- Neurocrine Biosciences upgraded by Evercore ISI with a new price targetEvercore ISI upgraded Neurocrine Biosciences from In-line to Outperform and set a new price target of $130.00
- Neurocrine Biosciences upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Neurocrine Biosciences from Equal-Weight to Overweight and set a new price target of $130.00 from $120.00 previously
- Neurocrine Biosciences upgraded by Goldman Sachs with a new price targetGoldman Sachs upgraded Neurocrine Biosciences from Neutral to Buy and set a new price target of $115.00
- Neurocrine Biosciences upgraded by JP Morgan with a new price targetJP Morgan upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $124.00
- Neurocrine Biosci upgraded by Barclays with a new price targetBarclays upgraded Neurocrine Biosci from Equal Weight to Overweight and set a new price target of $110.00